Drugs / MT-3995
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02900235 | Aug → Dec 2016 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02531568 | Jun → Aug 2015 | — | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02205372 | Jul 2014 → Aug 2015 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01889277 | Jul 2013 → Jan 2015 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT02923154 | Sep 2016 → Mar 2018 | metabolic dysfunction-associated steatohepatitis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02676401 | Feb 2016 → Aug 2017 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02517320 | Jul 2015 → Nov 2016 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 2 | NCT01756716 | Dec 2012 → Sep 2014 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01756703 | Nov 2012 → Aug 2014 | diabetic kidney disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MT-3995 | “We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic...” PMID 32974732 ↗ Sep 2020 |
| Known as | Apararenona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2181929 ↗ |
| Known as | apararenone | “PURPOSE: To characterize the clinical relevance of in vitro drug-drug interaction findings with apararenone (MT-3995), the effects of apararenone on the sensitive substrates of...” PMID 33153727 ↗ Nov 20201“We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic...” PMID 32974732 ↗ Sep 2020 |
| Action | Activate | “mineralocorticoid receptor agonist activity” PMID 32974732 ↗ Sep 2020 |
| Action | Inhibit | “Mineralocorticoid receptor antagonist” CHEMBL2181929 ↗ |
| Modality | Small molecule | “a non-steroidal compound” PMID 32974732 ↗ Sep 2020 |
| Route | Oral | “After a Single Oral Dose” NCT02900235 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL2181929 ↗ |